RTI Surgical (RTIX) entered into an agreement to acquire Zyga Technology, developer of the SImmetry® Sacroiliac Joint Fusion system.
Zyga's annual revenue is ~US $4MM. The company has also developed the Glyder® Facet Restoration Device. SImmetry is commercially available, while Glyder is not.
As of 2015, Zyga had raised nearly $50MM in a variety of fundings which in part supported clinical trials. SImmetry is entered in the ongoing EVoluSIon clinical trial; recruitment is terminated in a postmarket study of SImmetry in SI joint fusion and decortication. Zyga completed the GLISSADE clinical study to evaluate the safety of Glyder in participants with facet joint pain; recruitment is suspended for DUET, a U.S. study of Glyder in subjects with lumbar facet pain syndrome.
In 2015, analysts estimated the SI joint treatment market at under $70MM. Today, RTIX leadership cites an estimated $100MM market in the U.S., slated to exceed $200MM by 2024, with SI joint fusion procedures growing 20%.
In September 2017, Highmark expanded positive coverage for minimally invasive sacroiliac joint fusion, including all FDA-cleared instrumentation for this indication including cages or screws, with or without bone graft. Previously, the insurer had only covered SI-BONE's iFuse Implant System®. Highmark represents the 4th-largest Blue Cross and Blue Shield-affiliated insurer in the U.S.
As of 2015, SI-BONE reportedly claimed 85% of the market with iFuse. Other FDA-cleared SI devices are available from Camber Spine, CoreLink, Globus Medical, Life Spine, Medtronic, SI-BONE, SICAGE, SpineFrontier, X-Spine, etc.
Sources: RTI Surgical, Inc.; zyga.com; clinicaltrials.gov; ORTHOWORLD Inc.